
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc is positioned for significant growth, particularly with its POSLUMA product, which is expected to achieve high single-digit market share in PSMA PET imaging revenue, a notable increase from prior quarters. Additionally, the introduction of a new Pylarify formulary, which boosts batch sizes by approximately 50% and extends TPT eligibility for three years, is anticipated to revitalize growth for the product starting in the fourth quarter of 2026. Finally, the potential for enhanced contribution margins from non-Pylarify segments may lead to surpassing current EPS expectations for 2026-2027, further bolstering the company's financial outlook.
Bears say
Lantheus Holdings Inc. has reported a decline in Pylarify revenue, which amounted to $260 million, reflecting an 8% year-over-year decrease and falling short by approximately $14 million of market expectations. Additionally, the company experienced lower-than-expected growth in unit sales, achieving only a 2% increase year-over-year and facing a 10% price headwind during the quarter. Compounding these challenges, Lantheus Holdings' growth profile is now projected to lag behind that of profitable small to mid-cap MedTech peers for 2025-2026, suggesting an overall weak financial outlook.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares